Andrew Gengos - 02 Jun 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role: Officer
Signature: /s/ Mark Worthington, Attorney-in-fact for Andrew Gengos
Issuer symbol: ATHA
Transactions as of: 02 Jun 2023
Net transactions value: +$191,572
Form type: 4
Filing time: 06 Jun 2023, 19:36:20 UTC
Previous filing: 22 May 2023
Next filing: 09 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATHA	Common Stock	Purchase	$27,533	+10,012		$2.75	10,012	02 Jun 2023	Direct
transaction	ATHA	Common Stock	Purchase	$18,823	+6,582	+66%	$2.86	16,594	02 Jun 2023	Direct	F1
transaction	ATHA	Common Stock	Purchase	$10,066	+3,418	+21%	$2.94	20,012	02 Jun 2023	Direct
transaction	ATHA	Common Stock	Purchase	$45,000	+15,000	+75%	$3.00	35,012	05 Jun 2023	Direct	F2
transaction	ATHA	Common Stock	Purchase	$29,997	+10,000	+29%	$3.00	45,012	05 Jun 2023	Direct	F3
transaction	ATHA	Common Stock	Purchase	$29,999	+10,000	+22%	$3.00	55,012	05 Jun 2023	Direct
transaction	ATHA	Common Stock	Purchase	$30,154	+10,000	+18%	$3.02	65,012	05 Jun 2023	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.855 to $2.86, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
F2	The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.9999 to $3.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
F3	The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.995 to $3.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
F4	The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.995 to $3.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Remarks:

Chief Financial Officer and Chief Business Officer